Difference between revisions of "Osimertinib (Tagrisso)"
(Created page with "==General information== Class/mechanism from [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=747632 NCI Drug Dictionary]:An orally available, irreversible,...") |
(FDA approval) |
||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism | + | Class/mechanism: Mutant-selective EGFR tyrosine kinase inhibitor. Osimertinib preferentially binds irreversibly to certain mutant forms of the epidermal growth factor receptor (EGFR) (T790M, L858R, and exon 19 deletion) at approximately 9-times lower concentrations than wild-type. Two pharmacologically-active metabolites of osimertinib, AZ7550 and AZ5104, also emerge at about 10% the level of osimertinib. AZ7550 had similar potency to osimertinib. AZ5104 had about 8-times greater potency against exon 19 deletion and T790M mutants than osimertinib and 15-times greater potency against wild-type EGFR. Osimertinib also inhibits activity of HER2, HER3, HER4, ACK1, and BLK.<ref name=insert>[http://www.azpicentral.com/tagrisso/tagrisso.pdf Osimertinib (Tagrisso) package insert]</ref><ref>[[Media:Osimertinib.pdf | Osimertinib (Tagrisso) package insert (locally hosted backup)]]</ref><ref>[https://www.tagrisso.com/ Tagrisso manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
+ | |||
+ | ==Patient drug information== | ||
+ | *[http://www.azpicentral.com/tagrisso/tagrisso.pdf Osimertinib (Tagrisso) package insert]<ref name="insert"></ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | *11/13/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm FDA approved] "for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]], as detected by an FDA-approved test, who have progressed on or after [[:Category:EGFR_inhibitors|EGFR tyrosine kinase inhibitor (TKI)]] therapy." | + | *11/13/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm FDA approved] "for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]], as detected by an FDA-approved test, who have progressed on or after [[:Category:EGFR_inhibitors|EGFR tyrosine kinase inhibitor (TKI)]] therapy."<ref name="insert"></ref> |
==Also known as== | ==Also known as== |
Revision as of 07:19, 14 November 2015
General information
Class/mechanism: Mutant-selective EGFR tyrosine kinase inhibitor. Osimertinib preferentially binds irreversibly to certain mutant forms of the epidermal growth factor receptor (EGFR) (T790M, L858R, and exon 19 deletion) at approximately 9-times lower concentrations than wild-type. Two pharmacologically-active metabolites of osimertinib, AZ7550 and AZ5104, also emerge at about 10% the level of osimertinib. AZ7550 had similar potency to osimertinib. AZ5104 had about 8-times greater potency against exon 19 deletion and T790M mutants than osimertinib and 15-times greater potency against wild-type EGFR. Osimertinib also inhibits activity of HER2, HER3, HER4, ACK1, and BLK.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 11/13/2015: FDA approved "for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy."[1]
Also known as
AZD9291